AR035640A1 - Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas. - Google Patents

Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas.

Info

Publication number
AR035640A1
AR035640A1 ARP010102129A ARP010102129A AR035640A1 AR 035640 A1 AR035640 A1 AR 035640A1 AR P010102129 A ARP010102129 A AR P010102129A AR P010102129 A ARP010102129 A AR P010102129A AR 035640 A1 AR035640 A1 AR 035640A1
Authority
AR
Argentina
Prior art keywords
inhibitors
arteriosclerosis
prevention
treatment
manufacture
Prior art date
Application number
ARP010102129A
Other languages
English (en)
Original Assignee
Applied Research Systems
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Inst Nat Sante Rech Med filed Critical Applied Research Systems
Publication of AR035640A1 publication Critical patent/AR035640A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se trata, describe y reivindica el uso de inhibidores de IL-18 en la fabricación de medicamentos para el tratamiento y/o prevención de arteriosclerosis; método de tratamiento o prevención de arteriosclerosis utilizando dichos inhibidores; uso del IL-18 como marcador de mala prognosis clínica en fallas cardíacas. El uso que se describe y reivindica en esta solicitud está basado en el hallazgo que existe entre síndromes coronarios agudos y niveles elevados de IL-18 circulante, factores conducentes en la formación de placas ateroescleróticas, responsables de los paros cardíacos. Específicamente se trata del uso de inhibidores de la interleuquina (IL-18) inicialmente denominada interferón delta (IFN-delta) una citoquina proinflamatoria cuya inhibición es consecuente con la inhibición en el desarrollo, progresión y estabilidad de placas. Específicamente se reivindica el uso de inhibidores de IL-18 para la formulación y fabricación de medicamentos para la prevención de arteriosclerosis V. gr.: inhibidores como los anticuerpos contra IL-18 inhibidores-ICE, anticuerpos contra cualquiera de las subunidades de los receptores IL-18. También se describen y reivindican los objetos restantes mencionados en el encabezamiento.
ARP010102129A 2000-05-05 2001-05-04 Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas. AR035640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05

Publications (1)

Publication Number Publication Date
AR035640A1 true AR035640A1 (es) 2004-06-23

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102129A AR035640A1 (es) 2000-05-05 2001-05-04 Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas.

Country Status (33)

Country Link
US (1) US20040076628A1 (es)
EP (1) EP1278540B1 (es)
JP (1) JP5122053B2 (es)
KR (2) KR20030016254A (es)
CN (2) CN1841066B (es)
AR (1) AR035640A1 (es)
AT (1) ATE395075T1 (es)
AU (2) AU2001267390B2 (es)
BG (1) BG65881B1 (es)
BR (1) BRPI0110506B8 (es)
CA (1) CA2407895C (es)
CY (1) CY1110385T1 (es)
CZ (1) CZ300792B6 (es)
DE (1) DE60134009D1 (es)
DK (1) DK1278540T3 (es)
EA (2) EA007014B1 (es)
EE (1) EE05056B1 (es)
ES (1) ES2305082T3 (es)
HK (2) HK1055681A1 (es)
HR (1) HRP20020828A2 (es)
HU (1) HU229375B1 (es)
IL (2) IL152567A0 (es)
ME (1) ME00554B (es)
MX (1) MXPA02010895A (es)
NO (1) NO329821B1 (es)
PL (1) PL209371B1 (es)
PT (1) PT1278540E (es)
RS (1) RS50926B (es)
SI (1) SI1278540T1 (es)
SK (1) SK287761B6 (es)
UA (2) UA87658C2 (es)
WO (1) WO2001085201A2 (es)
ZA (1) ZA200208228B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (es) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
KR100857376B1 (ko) * 2001-01-29 2008-09-05 라보라토리스 세로노 에스.에이. 심장 질환의 치료 및/또는 예방에 사용되는 ｉｌ-18저해물질
KR20040030625A (ko) * 2001-05-25 2004-04-09 아레스 트레이딩 에스.에이. Ｃｎｓ 손상을 치료하거나 예방하기 위한 ｉｌ-18저해물질의 용도
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
BRPI0308663B8 (pt) * 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
EA010096B1 (ru) * 2003-03-11 2008-06-30 Лаборатуар Сероно Са Экспрессирующие векторы, содержащие ie2-промотор mcmv
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP2007532617A (ja) * 2004-04-15 2007-11-15 アテラ バイオテクノロジーズ エービー アテローム血栓症およびプラーク破壊を予防するためのアネキシンｖ
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
MX2016002719A (es) 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein

Also Published As

Publication number Publication date
SI1278540T1 (sl) 2008-10-31
SK15562002A3 (sk) 2003-05-02
HK1055681A1 (en) 2004-01-21
CN1250286C (zh) 2006-04-12
EE05056B1 (et) 2008-08-15
DK1278540T3 (da) 2008-07-21
UA78492C2 (en) 2007-04-10
KR100798545B1 (ko) 2008-01-28
PL365697A1 (en) 2005-01-10
HU229375B1 (en) 2013-11-28
PT1278540E (pt) 2008-07-03
CA2407895C (en) 2012-12-18
YU82602A (sh) 2006-01-16
JP5122053B2 (ja) 2013-01-16
BG107218A (bg) 2003-06-30
ME00554B (me) 2012-03-20
HUP0301991A3 (en) 2006-11-28
CN1841066A (zh) 2006-10-04
RS50926B (sr) 2010-08-31
BRPI0110506B8 (pt) 2021-05-25
US20040076628A1 (en) 2004-04-22
HUP0301991A2 (hu) 2003-09-29
JP2003532685A (ja) 2003-11-05
IL152567A (en) 2010-12-30
MEP64008A (en) 2011-12-20
NO20025307L (no) 2002-12-18
BR0110506A (pt) 2003-04-01
PL209371B1 (pl) 2011-08-31
MXPA02010895A (es) 2003-03-27
ES2305082T3 (es) 2008-11-01
CZ20023644A3 (cs) 2003-03-12
WO2001085201A3 (en) 2002-05-10
EP1278540A2 (en) 2003-01-29
EA005410B1 (ru) 2005-02-24
CY1110385T1 (el) 2015-04-29
WO2001085201A2 (en) 2001-11-15
BG65881B1 (bg) 2010-04-30
EA007014B1 (ru) 2006-06-30
CN1434722A (zh) 2003-08-06
ZA200208228B (en) 2005-07-27
NO20025307D0 (no) 2002-11-05
ATE395075T1 (de) 2008-05-15
CZ300792B6 (cs) 2009-08-12
HRP20020828A2 (en) 2004-12-31
BRPI0110506B1 (pt) 2015-05-19
DE60134009D1 (de) 2008-06-26
KR20030016254A (ko) 2003-02-26
EA200201175A1 (ru) 2003-04-24
NO329821B1 (no) 2010-12-27
AU6739001A (en) 2001-11-20
CN1841066B (zh) 2012-08-29
EA200401183A1 (ru) 2004-12-30
AU2001267390B2 (en) 2005-09-22
CA2407895A1 (en) 2001-11-15
KR20070073989A (ko) 2007-07-10
SK287761B6 (en) 2011-09-05
UA87658C2 (uk) 2009-08-10
IL152567A0 (en) 2003-05-29
EP1278540B1 (en) 2008-05-14
EE200200620A (et) 2004-06-15
HK1094909A1 (en) 2007-04-13

Similar Documents

Publication Publication Date Title
AR035640A1 (es) Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas.
UY27965A1 (es) Derivados heterocíclicos
SE8702980D0 (sv) Therapeutic use of serotonin antagonists
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
RS53767B1 (en) PROCEDURE FOR TREATMENT OF JOINT INJURY
NO970748L (no) Forbindelser, farmasöytisk blanding og diagnostisk anordning som omfatter de samme, og deres anvendelse
TR199802505T2 (xx) Sel�ler NA+/H+ de�i�tiricisinin (NHE) bir inhibit�r�n�n bir ilac�n �retiminde kullan�m�.
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
CO5590913A2 (es) Terapia de combinacion antivirica
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
PE20010747A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
NO170332C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-(4-hydroksy-3,5-di-tert.-butyl-benzoyl)-homopiperaziner
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
AR024476A1 (es) Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen.
NO993670L (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikamenter for behandling av AIDS
BRPI0315461B8 (pt) sistema terapêutico em forma de película
MX9207557A (es) Derivados de acidos benzofuranil- y tiofenilmetiltio-alcanocarboxilicos, procedimiento para su preparacion y medicamentos que los contienen.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
CO2022001218A2 (es) Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca

Legal Events

Date Code Title Description
FB Suspension of granting procedure